Hours

Minutes

Seconds

-40%

on all subscriptions*

Last hours

Enjoy this offer

* See conditions under "Our services"

ValiRx Plc is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of science into impactful medicines to improve patient lives. The Company provides the scientific, financial, and commercial framework for enabling rapid translation of science into clinical development. The Company selects and incubates novel drug candidates and guides them through an optimized process of development, from pre-clinical studies to clinical and investor-ready assets. Its product pipeline includes VAL201, VAL301, CLX001 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. CLX001 is a peptide in nanoparticle formulation and is designed for precision destruction of cancer cells to avoid excessive side effects.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
19/06/26	0.1850 p	0.00%	1,380,599
18/06/26	0.1850 p	0.00%	956,354
17/06/26	0.1850 p	0.00%	220,348
16/06/26	0.1850 p	0.00%	16,767,020
15/06/26	0.1850 p	0.00%	1,723,292

Delayed Quote London S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - London S.E. Other stock markets 16:35:25 19/06/2026 BST			5-day change	1st Jan Change
0.1850 ^GBX	0.00%		0.00%	-44.78%

06-02	ValiRx Completes Oncology Assets Evaluation Deal with Stingray Bio	MT
05-27	ValiRx subsidiary Cytolytix granted "core" European patent	AN

Market Cap	2.49M 3.29M 2.87M 2.65M 4.65M 310M 4.69M 31.47M 12.22M 153M 12.36M 12.1M 530M	P/E 2023	-2.94x	P/E 2024	-0.53x
Enterprise Value	944K 1.25M 1.09M 1M 1.77M 118M 1.78M 11.94M 4.64M 58.03M 4.69M 4.59M 201M	EV / Sales 2023	612,941,875x	EV / Sales 2024	27,264,249x
Free-Float	93.43%	Yield 2023 *	-	Yield 2024	-

06-02	ValiRx Completes Oncology Assets Evaluation Deal with Stingray Bio	MT
05-27	ValiRx subsidiary Cytolytix granted "core" European patent	AN
05-27	ValiRx Unit Wins European Patent for Anti-Cancer Peptide Patent	MT
05-21	ValiRx Raises Funds via Retail Offering	MT
05-18	ValiRx to Raise Funds via Retail Offer	MT
05-15	IAG launches new buyback; Forgent settles legal case	AN
05-15	WINNERS & LOSERS: Kendrick drilling results; Blackbird new approach	AN
05-15	ValiRx Seeks to Raise Over GBP1 Million via Share Issue	MT
05-14	WINNERS & LOSERS: Auction upgrades guidance; Aquila talks break down	AN
03-31	ValiRx PLC Announces Change Of Registered Office	CI
03-03	ValiRx establishes veterinary oncology-focused subsidiary	AN
03-02	ValiRx Forms Veterinary Oncology Unit	MT
03-02	ValiRx plc Sets Up Wholly Owned Subsidiary ValiRx Animal Health Limited	CI

24/03/25	ValiRx PLC - Director Disclosure Update	AQ
19/09/24	ValiRx plc - Inaphaea Evaluation and Commercial Use Agreement	AQ
06/12/23	ValiRx strikes deal with Ambrose Healthcare to license late-stage cancer treatment	AQ
01/02/23	ValiRx signals launch of new strategy with Nottingham laboratories	AQ
16/12/22	ValiRx appoints preclinical project manager to drive development of triple breast cancer treatment	AQ

ValiRx plc Share Price

Stocks

VAL

GB00BLH13C52

Biotechnology & Medical Research

Valuation: ValiRx plc

Chart: ValiRx plc

Latest news : ValiRx plc

Press Releases: ValiRx plc

Quotes and Performance

Course Extremes

Managers and Directors: ValiRx plc

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

Current month	-5.13%
1 month	-2.63%
3 months	-37.29%
6 months	-53.16%
Current year	-44.78%

1 week	0.18	0.19
1 month	0.17	0.21
Current year	0.17	0.48
1 year	0.17	0.88
3 years	0.17	15
5 years	0.17	65
10 years	0.17	1,436.25

Manager	Title	Age	Since
Mark Eccleston CEO	Chief Executive Officer	55	11/08/2024
Gerald Desler DFI	Director of Finance/CFO	81	-
Michelle Barnard CTO	Chief Tech/Sci/R&D Officer	-	26/03/2025

Director	Title	Age	Since
Gerald Desler BRD	Director/Board Member	81	31/08/2006
Catherine Tralau-Stewart BRD	Director/Board Member	62	24/07/2024
Martin Gouldstone CHM	Chairman	59	24/07/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
03-03	Mark Eccleston	Buy	Chief Executive Officer	1,000,000	0.1346%
17/10/22	Stella Panu	Free	Director	75,000	0.0832%
17/10/22	Stella Panu	Free	Director	75,000	0.0832%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VALIRX PLC	0.00%	0.00%	-66.36%	-97.61%	1.88M
ARGENX SE	+1.44%	-1.25%	+63.52%	+114.88%	54.44B
WUXI APPTEC CO., LTD.	+4.60%	+5.82%	+56.35%	+43.04%	45.8B
BIONTECH SE	-1.44%	+1.51%	-12.94%	-19.24%	22.98B
INSMED INCORPORATED	-2.69%	-0.95%	-3.68%	+379.00%	20.76B
WUXI BIOLOGICS (CAYMAN) INC.	+3.22%	+2.94%	+24.02%	-35.05%	16.25B
GENMAB A/S	+0.58%	+1.08%	+16.73%	-38.06%	15.34B
EXELIXIS, INC.	-1.01%	-2.97%	+27.42%	+171.92%	13.05B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+3.07%	+5.43%	+21.37%	-	12.37B
PHARMAESSENTIA CORPORATION	+4.95%	+13.49%	+121.11%	+249.05%	12.47B
Average	+1.27%	+1.68%	+24.75%	+85.33%	21.35B
Weighted average by Cap.	+1.63%	+1.38%	+39.56%	+98.70%

	2023	2024
Net sales	0.01 0.01 0.01 0.01 0.02 1.2 0.02 0.12 0.05 0.59 0.05 0.05 2.05	0.05 0.07 0.06 0.05 0.09 6.21 0.09 0.63 0.24 3.06 0.25 0.24 10.61
Net income	-2.04M -2.7M -2.35M -2.17M -3.81M -254M -3.84M -25.77M -10.01M -125M -10.12M -9.91M -434M	-1.92M -2.54M -2.21M -2.04M -3.58M -239M -3.61M -24.23M -9.41M -118M -9.52M -9.31M -408M
Net Debt	-153K -202K -176K -162K -286K -19.04M -288K -1.93M -750K -9.38M -758K -742K -32.52M	-1.54M -2.04M -1.78M -1.64M -2.89M -193M -2.91M -19.53M -7.59M -94.93M -7.67M -7.51M -329M